FDA Authorizes Intradermal Use of Jynneos Vaccine for Monkeypox

Maiya Focht

August 09, 2022

The US Food and Drug Administration (FDA) today authorized intradermal administration of the Jynneos vaccine for the treatment of monkeypox. The process, approved specifically for high-risk patients, was passed under the administration's Emergency Use Authorization. It follows the decision on August 4 by the US Department of Health and Human Services to declare monkeypox a public health emergency. Intradermal administration will allow providers to get five doses out of a one-dose vial.

Medscape Medical News will update this article as more information becomes available.

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.